Table 1 Baseline characteristics of study participants, overall and stratified according to whether they developed a NADC during prospective follow-up
All patients | Developed a NADC | |||
|---|---|---|---|---|
Yes | No | |||
Total number | 41746 (100.0) | 880 (100.0) | 40866 (100.0) | |
Gender*, n (%) | Male | 30572 (73.2) | 708 (80.5) | 29864 (73.1) |
Female | 11143 (26.7) | 172 (19.6) | 10971 (26.9) | |
Age (years) | Median (IQR) | 39 (33, 46) | 47 (41, 56) | 39 (33, 46) |
Mode of HIV acquisition, n (%) | Men having sex with men | 18251 (43.7) | 408 (46.4) | 17843 (43.7) |
Injection drug user | 6075 (14.6) | 153 (17.4) | 5922 (14.5) | |
Heterosexual | 14621 (35.0) | 256 (29.1) | 14365 (35.2) | |
Other/unknown | 2799 (6.7) | 63 (7.2) | 2736 (6.7) | |
Ethnic group, n (%) | White | 20870 (50.0) | 479 (54.4) | 20391 (49.9) |
Black | 2866 (6.9) | 27 (3.1) | 2839 (7.0) | |
Other | 838 (2.0) | 11 (1.3) | 827 (2.0) | |
Unknown/not collected | 17172 (41.1) | 363 (41.3) | 16809 (41.1) | |
BMI (kg/m2), n (%) | <18 | 1241 (3.0) | 39 (4.4) | 1202 (2.9) |
≥18, ≤26 | 24674 (59.1) | 521 (59.2) | 24153 (59.1) | |
>26, ≤30 | 4751 (11.4) | 99 (11.3) | 4652 (11.4) | |
>30 | 1643 (3.9) | 43 (4.9) | 1600 (3.9) | |
Unknown | 9437 (22.6) | 178 (20.2) | 9259 (22.7) | |
CD4 count (cells/mm3) | Median (IQR) | 434 (282, 620) | 393 (235, 583) | 435 (284, 621) |
Nadir CD4 count (cells/m3) | Median (IQR) | 223 (97, 377) | 144 (50, 290) | 225 (99, 379) |
HIV RNA (log10 copies/ml) | Median (IQR) | 2.3 (1.7, 4.3) | 1.7 (1.7, 3.9) | 2.3 (1.7, 4.3) |
Prior NADC, n (%) | 585 (1.4) | 48 (5.5) | 537 (1.3) | |
Prior ADC, n (%) | 2436 (5.8) | 91 (10.3) | 2345 (5.7) | |
Smoking status, n (%) | Current Smoker | 15526 (37.2) | 381 (43.3) | 15145 (37.1) |
Ex-smoker | 8121 (19.5) | 226 (25.7) | 7895 (19.3) | |
Never smoked | 10227 (24.5) | 151 (17.2) | 10076 (24.7) | |
Unknown | 7872 (18.9) | 122 (13.9) | 7750 (19.0) | |
HCV positive, n (%) | 4431 (10.6) | 105 (11.9) | 4326 (10.6) | |
HBV positive, n (%) | 1751 (4.2) | 56 (6.4) | 1695 (4.2) | |
Any use of ARV, n (%) | 27778 (66.5) | 718 (81.6) | 27060 (66.2) | |